Vaxcyte (PCVX) Revenue & Revenue Breakdown
Vaxcyte Revenue Highlights
Main Segment (Y)
Pneumococcal Conjugate Vaccine
Main Geography (Y)
Pneumococcal Conjugate Vaccine
Vaxcyte Revenue by Period
Vaxcyte Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Vaxcyte generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vaxcyte Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $14.45M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Vaxcyte generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Vaxcyte Revenue Breakdown
Vaxcyte Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 | Dec 20 |
|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B |
Vaxcyte's latest annual revenue breakdown by segment (product or service), as of Dec 21: Pneumococcal Conjugate Vaccine (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 22 | Mar 22 | Mar 21 | Jun 20 |
|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B | $7.00B | $7.00B |
Vaxcyte's latest quarterly revenue breakdown by segment (product or service), as of Jun 22: Pneumococcal Conjugate Vaccine (100.00%).
Vaxcyte Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 | Dec 20 |
|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B |
Vaxcyte's latest annual revenue breakdown by geography, as of Dec 21: Pneumococcal Conjugate Vaccine (100.00%).
Quarterly Revenue by Country
| Country | Jun 22 | Mar 22 | Mar 21 | Jun 20 |
|---|---|---|---|---|
| Pneumococcal Conjugate Vaccine | $7.00B | $7.00B | $7.00B | $7.00B |
Vaxcyte's latest quarterly revenue breakdown by geography, as of Jun 22: Pneumococcal Conjugate Vaccine (100.00%).
Vaxcyte Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| TECH | Bio-Techne | $1.16B | $289.46M |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| IMCR | Immunocore | $249.43M | $75.40M |
| STRO | Sutro Biopharma | $153.73M | $25.71M |
| TVTX | Travere Therapeutics | $145.24M | $62.90M |
| ACLX | Arcellx | $110.32M | $26.03M |
| MRUS | Merus | $43.95M | $11.77M |
| LQDA | Liquidia | $17.49M | $4.45M |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| AKRO | Akero Therapeutics | - | - |